Contract Development And Manufacturing Organizations (CDMO)

Challenges Facing Pharmaceutical Manufacturing

Sean Diver, president of DCAT speaks about the pharmaceutical industry’s role during the Covid-19 pandemic, trends in drug manufacturing, and key issues for the EU pharmaceutical industry.

The Coronavirus Crisis: Challenges and Opportunities for CMOs, CDMOs and CROs

The coronavirus crisis caused by the Covid-19 pandemic has uncovered problems that have been smoldering beneath the surface of the pharmaceutical industry — including CMOs/CDMOs and CROs — and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: Andrew Henderson, Sterling Pharma Solutions

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: Mark Quick, Recipharm

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: Peter Halkjaer-Knudsen, Raybow Pharmaceuticals

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: Matthew Moorcroft, Lonza

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: Alan Walker, Kaneka

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: David Zimmermann, Kalexsyn

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: Andrew Thompson, J-Star

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: Jean-Luc Herbeaux, Hovione

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: GianMarco Negrisoli, Flamma

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: Peter Pekos, Dalton Pharma Services

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Expert Interview: Michael Quirmbach, CordenPharma

So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.

Kymos Acquires Germany’s Prolytic

Spanish contract laboratory company Kymos has boosted its European presence with the takeover of Germany’s Prolytic. Financial details were not disclosed.

Advancing Sustainable Chemical Solutions

Without products based directly or indirectly on chemicals, life as we know it would be unsustainable. According to various sources, more than 95% of the products around us are either made by the chemical industry or involve at least one chemical process step in their manufacture.

High Standards and Innovation Experience

As a production and innovation partner, JRS Contract Manufacturing supports those involved in special projects in product development, series start-ups, implementation of marketing-relevant product features, process optimization or capacity expansion.

The Rise of HPAPI Molecules

For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.

Hovione Appoints Jean-Luc Herbeaux as Chief Operating Officer

Jean-Luc Herbeaux has been appointed as Chief Operating Officer (COO) of Hovione, effective May 1, 2020.

Chemical Process Research and Development

Agrochemical and Custom Manufacturing Industry: Connected Fates

The fate of the agrochemical innovation, development, product launch and production are strongly linked to the parallel development of the fine chemicals and custom manufacturing industry.

AGC Expands Spanish Facilities

Patient Centricity: The New Nexus for CDMOs

Rentschler Biopharma Extends Japanese Pact

German biopharmaceuticals contract development and manufacturing organization Rentschler Biopharma is extending and deepening its existing collaboration in Japan with Summit Pharmaceuticals International (SPI), a wholly owned subsidiary of Sumitomo.

Why CDMOs Should Consider Value-Based Pricing

Outsourcing product development and manufacturing has become for many pharmaceutical and biotech companies a strategic activity and an integral part of their business model.

Continuous Processing

Experts Statements: Gabriel Haering, Cerbios Pharma

The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021.

The Pharma CDMO Challenge

Arcinova Appoints Roger Kilburn as CEO

Ardena Launches Life Science Ingredients Arm

Olon Buys Indian API Plant

With this acquisition, Olon said it has successfully finalized its three-year development plan and will now move to its next target, which is to play an important role in manufacturing biologics APIs.

A Holistic System Approach

Unique Opportunity for Innovation and Improvement

A Visible Reference of Production-scale Micro Reaction Technology

A Technology on the Upswing

Benefits across Different Industries and Applications